在使用抗CD38单克隆抗体作为第一线治疗后,对下一次治疗的考虑
Monique Hartley-Brown1, Ateh Zinkeng1,2
1Dana-Farber Cancer Institute, Boston, MA.
Hematology. American Society of Hematology. Education Program
|December 9, 2023
概括
新确诊的多发性骨髓瘤患者通常会接受抗CD38单克隆抗体 (mAbs). 本综述涵盖了在抗CD38 mAb暴露或耐药性后对多发性髓瘤的后期治疗方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 新诊断的多发性骨髓瘤 (NDMM) 的前线治疗越来越多地结合了抗CD38单克隆抗体 (mAbs).
- 这种广泛使用导致患者频繁暴露,并且在疾病过程的早期可能对抗CD38 mAb治疗产生抗药性.
- 在初始抗CD38 mAb治疗后进展的患者需要有效的管理策略.
研究的目的:
- 审查多发性骨髓瘤 (MM) 患者在抗CD38 mAb治疗后出现疾病进展的治疗选择.
- 在这个特定的临床环境中讨论针对B细胞成熟抗原 (BCMA) 和非BCMA向的治疗方法.
- 提供有关在先前暴露于抗CD38 mAbs.后复发性/耐药性MM的管理的见解.
主要方法:
- 对多发性骨髓瘤 (MM) 的二线和三线治疗方法的文献综述.
- 专注于抗CD38 mAb暴露后疾病进展的患者的治疗策略.
- 分析现有的治疗选择,包括针对BCMA和非针对BCMA的药物.
主要成果:
- 对于在抗CD38 mAb治疗后进展的MM患者,存在多种治疗策略.
- 针对B细胞成熟抗原 (BCMA) 的疗法在复发/耐药环境中显示出前景.
- 非BCMA向的选择也为抗CD38mAbs.耐药的患者提供了可行的替代方案.
结论:
- 对多发性骨髓瘤的后续治疗决策必须考虑先前的抗CD38 mAb暴露和折射性.
- 一系列的治疗策略,包括新药,可用于在抗CD38 mAb治疗期间或之后进展的患者.
- 需要进一步的研究来确定在这个不断变化的治疗环境中治疗的最佳顺序和组合.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.4K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
142
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
142
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529